Arovella Therapeutics is pioneering the development of its innovative invariant Natural Killer T (iNKT) cell therapy platform, specifically targeting cancer treatment. Their lead program, ALA-101, focuses on CAR19-iNKT cells designed to combat blood cancers that express the CD19 marker, such as B cell lymphomas and leukemias. The unique aspect of iNKT cells is their ability to be engineered with a Chimeric Antigen Receptor (CAR), which allows them to recognize and eliminate cancer cells more effectively than conventional T cells. This engineering not only enhances their targeting capabilities but also mitigates the risk of graft versus host disease (GvHD), enabling the use of these cells from healthy donors as an "off-the-shelf" therapeutic option, thereby improving patient access to treatment.

In addition to ALA-101, Arovella is advancing ALA-105, which targets Claudin 18.2 (CLDN18.2), a novel tumor-associated antigen expressed in various solid tumors, including gastric and pancreatic cancers. The company employs a proprietary manufacturing process to genetically reprogram iNKT cells, enhancing their ability to infiltrate tumors and kill cancer cells through multiple mechanisms, including the NKG2D pathway. Arovella is also exploring strategies to "arm" CAR-iNKT cells with IL-12-TM, a modified cytokine that promotes cell proliferation and survival, further improving their antitumor efficacy. This comprehensive approach positions Arovella at the forefront of cell therapy innovation, aiming to transform cancer treatment paradigms.

Australia

Arovella Therapeutics (ASX: ALA) is the only Australian biotech developing an iNKT cell therapy platform to create therapies for people to live longer, healthier lives.

Cancer

Digestive System Diseases

Endocrine System Diseases

Hematologic Diseases

Immune System Diseases

Lymphatic Diseases

Arovella Therapeutics

Lymphoma

CAR19-iNKT

CAR-T Immunotherapy

Cell Therapies

Solid tumor/s

ALA-101

Breast cancer

Multiple myeloma

Non-small cell lung carcinoma

Pancreatic cancer

ALA-104

Biologics

Lentiviral Vector (LVV)

Therapeutic

Arovella Therapeutics

Company Details